Anika Therapeutics, Inc.
ANIKDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ANIK's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cingal | Phase 3 | Osteoarthritis, Knee | - | - |
Triamcinolone Hexacetonide | Phase 3 | Knee Osteoarthritis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Anika Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Anika Therapeutics, Inc.'s (ANIK) pipeline across Phase 3. Its lead program is Cingal (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Anika Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Anika Therapeutics, Inc. (ANIK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANIK biotech catalysts?→
Add ANIK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Anika Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.